US Foreign Bribery Investigations Ramp Up, With 'Carrot' For Cooperation
This article was originally published in PharmAsia News
Executive Summary
Pilot program from the US Department of Justice reduces fines for companies that voluntarily disclose misconduct; focus of investigations is broadening from sales to suppliers.
You may also be interested in...
Novartis Settles Foreign Bribery Charges With US Government
The company agreed to pay $233.9m to the US Department of Justice and $112m to the Securities and Exchange Commission to settle foreign bribery charges tied to South Korea, Vietnam and Greece.
Alexion Investigating Soliris Sales Practices, Delays Earnings Report
One analyst that has been tracking Alexion’s delayed SEC filing believes that a former employee’s allegation of improper Soliris sales is unlikely to represent widespread fraud.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.